AGP Executive Report
Last update: 3 hours agoEbola Screening Disruption: A passenger from the Congo was allowed onto an Air France flight to Detroit “in error,” despite new U.S. Ebola entry restrictions, prompting U.S. Customs to block the landing and divert the plane to Montreal instead. Public Health Pressure: The incident lands as Canada weighs World Cup crowd-readiness while officials track Ebola risk and travelers’ screening rules. Clinical Pipeline Update: Tiziana Life Sciences says enrollment is complete in its Phase 2a trial of intranasal foralumab for non-active secondary progressive multiple sclerosis, with topline results due late Q3 2026. Biotech Financing: Nanobiotix priced a large global follow-on offering and also flagged trading resumption after a temporary halt. Access & Care: Health Canada approval news continues to surface, including a new custom-fit CPAP mask after regulatory clearance.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
![[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)](https://ml.globenewswire.com/Resource/Download/b82cb0dd-e6c7-45cb-9174-713d3784302f/north-america-genome-editing-market-size-2025-to-2035-usd-billion-.png)
